Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Photochem Photobiol. 2011 Mar-Apr;87(2):474-7. doi: 10.1111/j.1751-1097.2010.00882.x. Epub 2011 Jan 24.
We recently showed that intranasal phototherapy represents an efficient therapeutic modality for the treatment of patients with seasonal allergic rhinitis (SAR). The aim of this pilot study was to compare the efficacy of intranasal phototherapy with that of the new generation antihistamine fexofenadine HCl in SAR. A randomized open study was conducted in patients with a history of moderate-to-severe ragweed-induced SAR. Thirty-one patients were randomly assigned to receive either intranasal irradiation three times a week for 2 weeks, or 180 mg fexofenadine HCl per day for 2 weeks. Each patient kept a diary of symptoms for nasal obstruction, nasal itching, rhinorrhea, sneezing and palate itching. Total nasal score (TNS), a sum of scores for nasal symptoms, was also calculated. In the rhinophototherapy group the individual scores significantly decreased compared with baseline for all of the parameters. In the fexofenadine HCl group none of the scores improved significantly at the end of the treatment except sneezing. TNS was significantly decreased in the rhinophototherapy group, but no significant change was observed in the fexofenadine HCl group after 2 weeks of treatment. In conclusion, we found that intranasal phototherapy is more efficient than fexofenadine HCl in reducing clinical symptoms for SAR.
我们最近表明，鼻内光疗是治疗季节性过敏性鼻炎（SAR）患者的有效治疗方法。本初步研究的目的是比较鼻内光疗与新一代抗组胺药盐酸非索非那定在 SAR 中的疗效。在有中度至重度豚草诱发 SAR 病史的患者中进行了一项随机开放研究。31 名患者被随机分配接受每周 3 次鼻内照射 2 周，或每天 180 毫克盐酸非索非那定 2 周。每位患者都记录了鼻塞、鼻痒、流涕、打喷嚏和腭痒的症状日记。还计算了总鼻评分（TNS），即鼻症状评分的总和。在光疗组中，与基线相比，所有参数的个体评分均显著降低。在盐酸非索非那定组中，除了打喷嚏外，治疗结束时没有任何评分显著改善。在光疗组中 TNS 显著降低，但在接受 2 周治疗后，在盐酸非索非那定组中未观察到显著变化。总之，我们发现鼻内光疗比盐酸非索非那定更能有效减轻 SAR 的临床症状。
